Clover Health has reached a critical profitability inflection, delivering back-to-back profitable quarters in Q1 and Q2 2026 with net income of $27.3M and $28.0M, respectively, driven by a sharp improvement in the combined ratio to 96.2% in Q2 2026 from 102.2%...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.05+29.4% vs $0.04 | $743M+2.0% vs $728M |
Q2 2026 May 6, 2026 | $0.07+0.0% vs $0.07 | $749M+4.8% vs $715M |
Q1 2026 Feb 26, 2026 | -$0.05+51.0% vs -$0.10 | $488M+4.4% vs $467M |
Q4 2025 Nov 4, 2025 | -$0.05-350.0% vs $0.02 | $497M+6.3% vs $467M |
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.
Tidal Investments LLC purchased a new stake in shares of Clover Health Investments, Corp. (NASDAQ: CLOV) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 411,409 shares of the company's stock, valued at approximately $2,156,000. Tidal Investments LLC owned 0.08%
Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report)'s stock price fell 6.5% during trading on Tuesday after an insider sold shares in the company. The company traded as low as $4.70 and last traded at $4.7690. Approximately 1,612,354 shares traded hands during trading, a decline of 74% from the average session volume of 6,101,653
WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.
Benchmark CLOV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Clover Health Investments, Corp. (CLOV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.57 | $2.37B | -26.88 | 40.34% | -4.45% | -26.33% | — | |
| $374.80 | $45B | 38.09 | 10.06% | 0.88% | 6.89% | — | |
| $85.86 | $109.55B | 61.77 | 7.85% | 1.18% | 6.41% | — | |
| $398.56 | $86.44B | 15.87 | 12.62% | 2.47% | 11.2% | — | |
| $62.07 | $30.66B | -4.56 | 19.44% | -2.63% | -23.94% | — | |
| $189.37 | $9.89B | 21.23 | 11.75% | -0.02% | -0.17% | — |
Clover Health Investments, Corp. (CLOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Clover Health Investments, Corp. (CLOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 17, 2026·SEC
Jun 18, 2026·SEC
Get notified when CLOV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Clover Health Investments, Corp. (CLOV) stock FAQ — growth, dividends, profitability & financials explained
Clover Health Investments, Corp. (CLOV) grew revenue by 40.3% over the past year. This is strong growth.
Clover Health Investments, Corp. (CLOV) reported a net loss of $18.4M for fiscal year 2025.
Clover Health Investments, Corp. (CLOV) has a return on equity (ROE) of -26.3%. Negative ROE indicates the company is unprofitable.
Clover Health Investments, Corp. (CLOV) has a combined ratio of 104.4%. A ratio above 100% means claims and expenses exceed premiums.
